Univest
Univest
  • Markets

Aarti Pharmalabs Analyst Review 2027: Profit Up 2.5 Times in a Year as the Stock Nears a Record

  • November 17, 2026
  • Posted by: Kunal Singla
  • Category: Market
No Comments
Aarti Pharmalabs Analyst Review 2027: Profit Up 2.5 Times in a Year as the Stock Nears a Record

Aarti Pharmalabs Stock Snapshot (16 Nov 2026 close)

  • Current Market Price (CMP): ₹986.75
  • 52-Week High / Low: ₹1,023.80 / ₹585.00
  • Market Capitalisation: ₹8,943 crore
  • P/E Ratio vs Industry P/E: 34.8 vs 40.7
  • Latest Quarter (Q2 FY27) Revenue: ₹610.5 crore (consolidated)
  • Latest Quarter (Q2 FY27) Net Profit: ₹71.5 crore (consolidated)

Quick Answer: The Aarti Pharmalabs analyst review 2027 follows a sharp recovery. Q2 FY27 revenue rose about 46% to a record ₹610.5 crore, EBITDA jumped about 80% to ₹134.6 crore and profit rose to ₹71.5 crore from ₹27.9 crore a year earlier. Management is guiding 15% to 18% annual growth in revenue and EBITDA over the next three to four years. We could not verify a current, dated brokerage target, so there is no published Aarti Pharmalabs share price target 2027 to cite. At ₹986.75, the stock is about 4% below its 52-week high and 69% above its low.

The Aarti Pharmalabs analyst review 2027 describes a company that has moved quickly from a weak FY26 to record quarters. For readers tracking the Aarti Pharmalabs share price target 2027, the September 2026 quarter delivered the highest revenue in the company’s history, and profit was roughly 2.5 times the year-ago level.

Aarti Pharmalabs closed at ₹986.75 on 16 November 2026, close to its 52-week high of ₹1,023.80 and well above its low of ₹585. This Aarti Pharmalabs analyst review 2027 covers coverage, results, the business, expansion plans and the factors behind the Aarti Pharmalabs stock outlook 2027.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Say in the Aarti Pharmalabs Analyst Review 2027
  • Q2 FY27 Results in the Aarti Pharmalabs Analyst Review 2027
  • How Aarti Pharmalabs Makes Money
  • Growth Triggers in the Aarti Pharmalabs Analyst Review 2027
  • Key Risks in the Aarti Pharmalabs Analyst Review 2027
  • Aarti Pharmalabs Analyst Review 2027: Stock at a Glance
  • Shareholding Trend
  • What to Watch After the Aarti Pharmalabs Analyst Review 2027
  • Final Word on the Aarti Pharmalabs Analyst Review 2027
  • Frequently Asked Questions
    • What does the Aarti Pharmalabs analyst review 2027 show?
    • Is there an Aarti Pharmalabs share price target 2027 from brokerages?
    • Why did profit jump in the Aarti Pharmalabs analyst review 2027 quarter?
    • What does Aarti Pharmalabs do?
    • Is Aarti Pharmalabs expensive, according to the Aarti Pharmalabs analyst review 2027?
    • What risks does the Aarti Pharmalabs analyst review 2027 highlight?
    • What should investors track after the Aarti Pharmalabs analyst review 2027?

What Analysts Say in the Aarti Pharmalabs Analyst Review 2027

Brokerage Rating Target Price Date
No verified current coverage Not available Not available As of November 2026

ICICI Direct has written on Aarti Pharmalabs in the past, but we could not find a dated 2026 brokerage report with a current rating and target. For a company with a market value near ₹8,900 crore, that is a notable gap.

So this Aarti Pharmalabs analyst review 2027 relies on company results and management guidance. Readers should be careful with any Aarti Pharmalabs share price target 2027 that does not cite a named research house and a date.

Q2 FY27 Results in the Aarti Pharmalabs Analyst Review 2027

Metric Q2 FY27 Q2 FY26 Change
Revenue from Operations ₹610.5 crore ₹418.3 crore +45.9%
EBITDA ₹134.6 crore ₹74.8 crore +80.2%
EBITDA Margin about 22.0% about 17.9% +4.1 pts
Net Profit ₹71.5 crore ₹27.9 crore +156%

The base matters here. The September 2025 quarter was weak, with revenue down about 9% from the year before, so part of the jump is recovery. Even so, the sequence is strong: revenue was ₹536 crore in the June 2026 quarter and ₹610.5 crore in September, and EBITDA has nearly doubled over four quarters, from about ₹75 crore to about ₹135 crore.

The Aarti Pharmalabs analyst review 2027 margin story is the best part. EBITDA grew almost twice as fast as revenue, lifting the margin by about four points. That points to better product mix and higher plant utilisation rather than just more volume.

How Aarti Pharmalabs Makes Money

Aarti Pharmalabs was carved out of Aarti Industries and listed separately in 2023. It is part of the wider Aarti group, alongside companies such as Aarti Drugs. Its businesses are:

  • Active pharmaceutical ingredients: generic APIs supplied to formulation makers in India and abroad.
  • Intermediates: chemical building blocks used in drug manufacturing.
  • Xanthine derivatives: caffeine and related products used in beverages, food and pharmaceuticals.
  • Contract development and manufacturing (CDMO): making molecules for innovator pharma companies under long-term contracts.

CDMO is the highest-value segment, because it ties Aarti to a client’s drug for years. That is why the Aarti Pharmalabs analyst review 2027 focuses on how fast CDMO and xanthines can scale.

Growth Triggers in the Aarti Pharmalabs Analyst Review 2027

  • Medium-term guidance: management targets 15% to 18% compound annual growth in revenue and EBITDA over the next three to four years.
  • Capacity expansion: the company outlined expansion in CDMO, APIs and xanthine derivatives alongside the Q2 results.
  • Margin gains: a margin near 22% leaves room for profit to keep outpacing sales if mix improves further.
  • Recovery from FY26: FY26 revenue fell to about ₹1,829 crore from ₹2,125 crore, so FY27 should show strong full-year growth.
  • Global supply shifts: pharma companies diversifying away from single-country supply chains favour Indian API and CDMO players.

Key Risks in the Aarti Pharmalabs Analyst Review 2027

  • Low base effect: growth rates will slow once FY27 laps the stronger quarters.
  • Customer concentration: CDMO revenue often depends on a few large clients.
  • Regulatory risk: plant inspections by global regulators can delay supplies.
  • Promoter stake decline: promoter holding fell to 39.66% from 42.88% in a year.
  • Valuation after rally: the stock has risen about 69% from its low.
  • No current research coverage: no recent external estimates to test guidance.

Compare Aarti Pharmalabs With API and CDMO Peers on the Univest Screener

Aarti Pharmalabs Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (16 Nov 2026 close) ₹986.75
52-Week High / Low ₹1,023.80 / ₹585.00
Market Capitalisation ₹8,943 crore
P/E (TTM) vs Industry 34.8 vs 40.7
Price to Book 3.97
Book Value per Share ₹248.65
Return on Equity 11.38%
Debt to Equity 0.40
FY26 Revenue / Net Profit ₹1,829 crore / ₹175 crore

The trailing P/E of about 35 is below the pharma industry average near 41. Because recent quarters are much stronger than FY26, the Aarti Pharmalabs analyst review 2027 suggests the forward multiple is lower than the trailing figure shows.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 42.88% 39.66% -3.22 pts
Foreign Institutions (FII) 8.02% 8.15% +0.13 pts
Domestic Institutions (DII) 6.96% 8.40% +1.44 pts
Public 42.14% 43.79% +1.65 pts

The promoter holding, spread across members of the Gogri family, fell by more than three points over the year. Domestic institutions added about 1.4 points. A falling promoter stake during a rising price is worth watching closely in the Aarti Pharmalabs analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Aarti Pharmalabs Analyst Review 2027

  • Q3 FY27 margin: whether EBITDA margin holds above 20%.
  • CDMO contracts: new client wins and commercial launches.
  • Capex timeline: commissioning of expansion in APIs and xanthines.
  • Promoter activity: any further change in family holdings.
  • Research initiation: a fresh dated report would provide an Aarti Pharmalabs share price target 2027 benchmark.

Final Word on the Aarti Pharmalabs Analyst Review 2027

The Aarti Pharmalabs analyst review 2027 shows a strong turnaround: record revenue, EBITDA up 80%, margins about four points higher and guidance for 15% to 18% growth for several years. The stock has responded and sits near its high.

With no current brokerage target and a falling promoter stake, the Aarti Pharmalabs stock outlook 2027 depends on proving that the margin gains are durable once the easy comparison with a weak FY26 fades. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Aarti Pharmalabs analyst review 2027 show?

It shows record Q2 FY27 revenue of ₹610.5 crore, up about 46%, and EBITDA up about 80% to ₹134.6 crore. Net profit rose to ₹71.5 crore from ₹27.9 crore. No current, dated brokerage target could be verified.

Is there an Aarti Pharmalabs share price target 2027 from brokerages?

We could not find a dated 2026 brokerage report with a current target for Aarti Pharmalabs. ICICI Direct has covered the company in the past. The stock closed at ₹986.75 on 16 November 2026.

Why did profit jump in the Aarti Pharmalabs analyst review 2027 quarter?

Revenue grew about 46% and the EBITDA margin rose to about 22% from 18%. The year-ago quarter was weak, with revenue down about 9%, which flatters the comparison. Profit therefore rose about 156%.

What does Aarti Pharmalabs do?

It makes active pharmaceutical ingredients, intermediates and xanthine derivatives such as caffeine. It also runs a contract development and manufacturing business for innovator drug companies. It was separated from Aarti Industries and listed in 2023.

Is Aarti Pharmalabs expensive, according to the Aarti Pharmalabs analyst review 2027?

The stock trades at a trailing P/E of about 34.8, below the industry figure of about 40.7. Price to book is 3.97 and return on equity is 11.38%. Recent quarterly profits are much higher than FY26, so the forward multiple is lower.

What risks does the Aarti Pharmalabs analyst review 2027 highlight?

The main risks are a fading low-base effect, CDMO customer concentration and regulatory inspections. Promoter holding fell to 39.66% from 42.88% in a year. The stock has also risen about 69% from its 52-week low.

What should investors track after the Aarti Pharmalabs analyst review 2027?

Track whether EBITDA margin stays above 20% and whether new CDMO contracts are signed. Watch the timeline for API and xanthine capacity expansion. Management’s 15% to 18% growth guidance is the yardstick for coming quarters.



2027 Aarti Pharmalabs Analyst Review pharmaceuticals
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply